Innovation1 Biotech Inc. (IVBT)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 75.99 Thousand USD | -99.83% |
| 2022 | 43.96 Million USD | 24070.86% |
| 2021 | 181.88 Thousand USD | -12.81% |
| 2020 | 208.6 Thousand USD | -18.65% |
| 2019 | 256.41 Thousand USD | -70.28% |
| 2018 | 862.74 Thousand USD | 12677.59% |
| 2017 | 6752.00 USD | 32.18% |
| 2016 | 5108.00 USD | 770.19% |
| 2015 | 587.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 3.83 Million USD | -9.64% |
| 2023 FY | 75.99 Thousand USD | -99.83% |
| 2023 Q4 | 75.99 Thousand USD | -98.03% |
| 2023 Q3 | 3.85 Million USD | 0.0% |
| 2023 Q2 | 3.85 Million USD | 0.54% |
| 2022 Q3 | 81.16 Million USD | -1.93% |
| 2022 Q1 | 84.37 Million USD | 46290.96% |
| 2022 FY | 43.96 Million USD | 24070.86% |
| 2022 Q2 | 82.76 Million USD | -1.91% |
| 2022 Q4 | 4.24 Million USD | -94.77% |
| 2021 Q2 | 138.65 Thousand USD | -27.12% |
| 2021 Q4 | 181.88 Thousand USD | 187.91% |
| 2021 FY | 181.88 Thousand USD | -12.81% |
| 2021 Q3 | 63.17 Thousand USD | -54.44% |
| 2021 Q1 | 190.24 Thousand USD | -8.8% |
| 2020 Q1 | 369.82 Thousand USD | 44.23% |
| 2020 FY | 208.6 Thousand USD | -18.65% |
| 2020 Q4 | 208.6 Thousand USD | -67.94% |
| 2020 Q3 | 650.72 Thousand USD | 2.89% |
| 2020 Q2 | 632.47 Thousand USD | 71.02% |
| 2019 Q1 | 603 Thousand USD | -30.11% |
| 2019 FY | 256.41 Thousand USD | -70.28% |
| 2019 Q4 | 256.41 Thousand USD | -22.64% |
| 2019 Q3 | 331.47 Thousand USD | -29.45% |
| 2019 Q2 | 469.83 Thousand USD | -22.08% |
| 2018 Q4 | 862.74 Thousand USD | 1112.74% |
| 2018 FY | 862.74 Thousand USD | 12677.59% |
| 2018 Q3 | 71.14 Thousand USD | 3.83% |
| 2018 Q1 | 62.99 Thousand USD | 832.95% |
| 2018 Q2 | 68.51 Thousand USD | 8.77% |
| 2017 FY | 6752.00 USD | 32.18% |
| 2017 Q1 | 473.00 USD | -90.74% |
| 2017 Q3 | 2901.00 USD | 1418.85% |
| 2017 Q2 | 191.00 USD | -59.62% |
| 2017 Q4 | 6752.00 USD | 132.75% |
| 2016 Q1 | 3856.00 USD | 556.9% |
| 2016 Q4 | 5108.00 USD | 0.02% |
| 2016 Q3 | 5107.00 USD | 373.31% |
| 2016 Q2 | 1079.00 USD | -72.02% |
| 2016 FY | 5108.00 USD | 770.19% |
| 2015 FY | 587.00 USD | 0.0% |
| 2015 Q4 | 587.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | 74.595% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 98.675% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 99.483% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 99.757% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | 97.64% |
| Better Therapeutics, Inc. | 22.94 Million USD | 99.669% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 99.735% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | 97.961% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 99.63% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 99.64% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 99.882% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | 96.771% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 99.893% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 99.709% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 99.376% |
| Molecular Templates, Inc. | 35.38 Million USD | 99.785% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | 98.262% |
| NexImmune, Inc. | 8.59 Million USD | 99.116% |
| Orgenesis Inc. | 14.55 Million USD | 99.478% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 99.356% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | 39.031% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | 98.662% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | 80.627% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 99.984% |
| Statera Biopharma, Inc. | 21.16 Million USD | 99.641% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 99.248% |
| Trevena, Inc. | 40.6 Million USD | 99.813% |
| Vaxxinity, Inc. | 44.35 Million USD | 99.829% |
| Vaccinex, Inc. | 3.63 Million USD | 97.907% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -91.631% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 99.866% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | 86.325% |